(24/7 MARKET NEWS) – Hoth Therapeutics, Inc. (NASDAQ: HOTH) reported, this morning, that its HT-ALZ developmental Alzheimer’s disease treatment achieved positive preclinical results that outpaced its pervious study.
Hoth Therapeutics is trading at $2.64, up $0.76 (+40.42%), on 154.81K premarket shares traded.
Its 52-week range is $ 1.52 to $17.4875. If its trading volume increases, it could break through the resistance between here and the $5 range.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.